Who is eligible for clinical trial NCT06174753?

Participants must meet the protocol's inclusion criteria for ST Elevation Myocardial Infarction. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06174753 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-18

Dapagliflozin in STEMI (NCT06174753)

The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Ottawa Heart Institute Research Corporation

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (22 items).

Location: University of Ottawa Heart Institute — Ottawa, Ontario

Age range: 18 Years

🧪 Interventions in This Study

Dapagliflozin 10mg Tab (DRUG)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients referred for PPCI meeting the following criteria are eligible for the study:
Ischemic chest discomfort of ≥30 minutes duration, and
Onset of chest pain ≤12 hours prior to entry into the study, and
One of the following High-Risk criteria on a standard 12 lead ECG: a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \>20mm

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Age \< 18 years
Any contraindication to undergo CMR imaging
Killip 4 (Cardiogenic shock on presentation)
Therapy with SGLT2i within last 8 weeks
Type 1 diabetes mellitus
Pregnancy
Nursing mother
Unwilling to use appropriate forms of contraception, as applicable
Chronic symptomatic HF with prior hospitalization for HF within the last year
hospitalization
Known history of prior MI

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Ottawa Heart Institute — Ottawa, Ontario

📞 Contact the Study Coordinator

Phone: (613) 696-7000

Email: pmacphee@ottawaheart.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in ST Elevation Myocardial Infarction

Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution — Cleveland, Ohio

Explore by condition: All ST Elevation Myocardial Infarction clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗